{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:57:08Z","timestamp":1793912228374,"version":"4.8.0"},"reference-count":25,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Nirsevimab was indicated in a population level for all infants &lt; 6 months during the 2023\u20132024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for RSV bronchiolitis. Methods: A retrospective observational cohort study was conducted in nine relevant hospitals from all provinces of Andalusia, a region with over 9 million inhabitants. The study sample included 222 children, divided into two groups: infants administered with nirsevimab for passive immunisation (exposure) and infants not administered with nirsevimab. Clinical outcomes were analysed, including the use of respiratory support, the need for admission to paediatric intensive care unit (PICU), and duration of hospitalisation. Bivariate analyses were performed, and multivariable logistic regression models were designed to calculate adjusted odds ratios (ORa), and Cox regression models to calculate adjusted hazard ratios (HRa). Results: Bivariate analysis showed an association between passive immunisation with nirsevimab and a lower frequency of numerous outcomes. After adjustment for relevant covariates, multivariable models showed that the exposure (nirsevimab) reduced nasal cannula use by 64% (13\u201385%), invasive or non-invasive mechanical ventilation by 48% (1\u201373%), PICU admission by 54% (14\u201375%), length of hospitalisation by 30% (8\u201347%), and length of nasal cannula by 31% (7\u201349%). A higher risk of co-infection was observed in those immunised (aOR = 3.42, 95%CI: 1.52\u20137.68). Conclusions: Passive immunisation with nirsevimab may decrease the severity of RSV bronchiolitis in infants requiring hospitalisation, thus contributing tertiary prevention that extends beyond the prevention of RSV infection.<\/jats:p>","DOI":"10.3390\/vaccines13020175","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:25:57Z","timestamp":1739355957000},"page":"175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023\u20132024 Season in Andalusia, Spain (NIRSEGRAND)"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7017-4095","authenticated-orcid":false,"given":"David","family":"Moreno-P\u00e9rez","sequence":"first","affiliation":[{"name":"Health and Consumption Department, General Directorate of Public Health and Pharmaceutical Management of Andalusia, 41020 Seville, Spain"},{"name":"Department of Paediatrics at the Malaga Mother-and-Child Hospital, Hospital Regional Universitario de M\u00e1laga, 29011 M\u00e1laga, Spain"},{"name":"Multidisciplinary Group for Paediatric Research, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), University of M\u00e1laga, 29010 M\u00e1laga, Spain"},{"name":"Faculty of Medicine, University of M\u00e1laga, 29071 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Korobova","sequence":"additional","affiliation":[{"name":"Service of Preventive Medicine and Public Health, Hospital Universitario San Cecilio, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Borja","family":"Croche-Santander","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5786","authenticated-orcid":false,"given":"Ana","family":"Cord\u00f3n-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Regional Universitario de M\u00e1laga, 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"D\u00edaz-Morales","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Universitario Reina Sofia, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-0060","authenticated-orcid":false,"given":"Leticia","family":"Mart\u00ednez-Campos","sequence":"additional","affiliation":[{"name":"Service of Paediatric Infectious Diseases, Hospital Materno Infantil Infanta Leonor, Hospital Universitario Torrec\u00e1rdenas, 04009 Almer\u00eda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"P\u00e9rez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Virgen Macarena, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen","family":"Mart\u00ednez-Padilla","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-961X","authenticated-orcid":false,"given":"Juan Luis","family":"Santos-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Brioso-Galiana","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, 21005 Huelva, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0132-3015","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"S\u00e1nchez-C\u00f3dez","sequence":"additional","affiliation":[{"name":"Service of Paediatrics, Hospital Universitario Puerta del Mar, 11009 C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Del Diego-Salas","sequence":"additional","affiliation":[{"name":"General Directorate of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, 41020 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rivera-Izquierdo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain"},{"name":"Centros de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lorusso","sequence":"additional","affiliation":[{"name":"Service of Surveillance and Occupational Health, General Directorate of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, 41020 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1016\/S2214-109X(17)30348-0","article-title":"Respiratory syncytial virus mortality among young children","volume":"5","author":"Weinberg","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2341505","DOI":"10.1080\/21645515.2024.2341505","article-title":"Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody","volume":"20","author":"Treston","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of Respiratory Syncytial Virus Vaccines in Adults Aged \u226560 Years: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2025, January 03). Ficha T\u00e9cnica Beyfortus 100 mg Soluci\u00f3n Inyectable en Jeringa Precargada [Technical Datasheet Beyfortus 100 mg Solution for Injection in Prefilled Syringe]. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1221689004\/FT_1221689004.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials","volume":"7","author":"Madhi","year":"2023","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Eng. J. Med."},{"key":"ref_8","unstructured":"Ministerio de Sanidad, Gobierno de Espa\u00f1a (2025, January 03). Recomendaciones de Utilizaci\u00f3n de Nirsevimab Para la Prevenci\u00f3n del Virus Respiratorio Sincitial (VRS) Para la Temporada 2023\u20132024 [Recommendations for the Use of Nirsevimab for the Prevention of respiratory Syncytial Virus (RSV) for the 2023\u20132024 Season]. Available online: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/Nirsevimab_2023.pdf."},{"key":"ref_9","unstructured":"Ministerio de Sanidad, Gobierno de Espa\u00f1a (2025, January 03). Actualizaci\u00f3n de Recomendaciones de Utilizaci\u00f3n de Nirsevimab [Update of Recommendations for the Use of Nirsevimab]. Available online: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/NirsevimabActualizacion.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Turalde-Mapili, M.W.R., Mapili, J.A.L., Turalde, C.W.R., and Pagcatipunan, M.R. (2023). The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis. Front. Pediat., 11.","DOI":"10.3389\/fped.2023.1132740"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ricc\u00f2, M., Cascio, A., Corrado, S., Bottazzoli, M., Marchesi, F., Gili, R., Giuri, P.G., Gori, D., and Manzoni, P. (2024). Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024). Vaccines, 12.","DOI":"10.3390\/vaccines12060640"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N. Eng. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/ppul.27041","article-title":"Monoclonal antibody therapies in respiratory syncytial virus prophylaxis-An umbrella review","volume":"59","author":"Kuitunen","year":"2024","journal-title":"Pediat. Pulmonol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: Initial results of a population-based longitudinal study","volume":"24","author":"Mallah","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","first-page":"2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","year":"2024","journal-title":"Euro Surveill."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Barbas Del Buey, J.F., \u00cd\u00f1igo Mart\u00ednez, J., Guti\u00e9rrez Rodr\u00edguez, M.\u00c1., Alonso Garc\u00eda, M., S\u00e1nchez-G\u00f3mez, A., Lasheras Carbajo, M.D., Jim\u00e9nez Bueno, S., Esteban Vasallo, M.D., L\u00f3pez Zambrano, M.A., and Calvo Rey, C. (2024). The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): A prospective population-based cohort study. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1441786"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","article-title":"Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: A retrospective cohort study in infants in Catalonia (Spain)","volume":"109","author":"Coma","year":"2024","journal-title":"Arch. Dis. Child."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e13294","DOI":"10.1111\/irv.13294","article-title":"Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1\u2009Year, Weeks 40, 2023, to 8, 2024, Spain","volume":"18","author":"Mazagatos","year":"2024","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_21","unstructured":"Spanish Ministry of Health (2025, January 26). Evaluaci\u00f3n de la Vacunaci\u00f3n Frente a VRS en la Poblaci\u00f3n Adulta [Evaluation of RSV Vaccination in Adult Population], Available online: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/VRS_adultos.pdf."},{"key":"ref_22","first-page":"1097","article-title":"Impact of nirsevimab on respiratory syncytial virus bronchiolitis in hospitalized infants: A real-world study","volume":"10","author":"Jeziorski","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sender, V., Hentrich, K., and Henriques-Normark, B. (2021). Virus-induced changes of the respiratory tract environment promote secondary infections with Streptococcus pneumoniae. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.643326"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00430-018-0567-9","article-title":"Identification of complement-related host genetic risk factors associated with influenza A(H1N1)pdm09 outcome: Challenges ahead","volume":"208","author":"Chatzopoulou","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus\u2013Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season\u2014New Vaccine Surveillance Network, October 2023\u2013February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:32:15Z","timestamp":1760027535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/2\/175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["vaccines13020175"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13020175","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}